> top > docs > PMC:7228307 > spans > 52066-52502 > annotations

PMC:7228307 / 52066-52502 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id tao:has_standard_notation
1044 342-346 Gene denotes FcγR Gene:2213
1045 98-102 Gene denotes FcγR Gene:2213
1046 50-54 Gene denotes FcγR Gene:2213
1047 170-177 Chemical denotes leucine MESH:D007930
1048 245-252 Chemical denotes alanine MESH:D000409
1049 400-410 Chemical denotes teplizumab MESH:C502540
1050 415-425 Chemical denotes spesolimab
1051 254-265 Mutation denotes L234A L235A p.L234,235A,A

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T404 23-33 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T405 170-177 Body_part denotes leucine http://purl.org/sig/ont/fma/fma82757
T406 245-252 Body_part denotes alanine http://purl.org/sig/ont/fma/fma82749

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T880 20-22 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T881 50-52 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T882 98-100 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T883 112-113 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T884 224-228 http://purl.obolibrary.org/obo/CLO_0007179 denotes L235
T885 342-344 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T68471 23-33 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T62086 23-28 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T40175 29-33 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T80744 170-177 Chemical denotes leucine http://purl.obolibrary.org/obo/CHEBI_25017
T54623 245-252 Chemical denotes alanine http://purl.obolibrary.org/obo/CHEBI_16449

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T54 23-33 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T55 170-177 Chemical denotes leucine http://purl.obolibrary.org/obo/CHEBI_25017
T56 245-252 Chemical denotes alanine http://purl.obolibrary.org/obo/CHEBI_16449

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes pubann:has_HGVS_notation
1044 342-346 Gene denotes FcγR Gene:2213
1045 98-102 Gene denotes FcγR Gene:2213
1046 50-54 Gene denotes FcγR Gene:2213
1047 170-177 Chemical denotes leucine MESH:D007930
1048 245-252 Chemical denotes alanine MESH:D000409
1049 400-410 Chemical denotes teplizumab MESH:C502540
1050 415-425 Chemical denotes spesolimab
1051 254-265 Mutation denotes L234A L235A p.L234,235A,A

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T296 0-111 Sentence denotes Modification to the Fc amino acid sequence of the FcγR‐contact regions can also be used to reduce FcγR binding.
T297 112-267 Sentence denotes A widely used modification of IgG1 is the substitution of leucine 234 and 235 in the lower hinge sequence (L234 L235 G236 G237) with alanine (L234A L235A).
T298 268-436 Sentence denotes It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4).

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T403 23-33 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T404 170-177 Body_part denotes leucine http://purl.org/sig/ont/fma/fma82757
T405 245-252 Body_part denotes alanine http://purl.org/sig/ont/fma/fma82749

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T296 0-111 Sentence denotes Modification to the Fc amino acid sequence of the FcγR‐contact regions can also be used to reduce FcγR binding.
T297 112-267 Sentence denotes A widely used modification of IgG1 is the substitution of leucine 234 and 235 in the lower hinge sequence (L234 L235 G236 G237) with alanine (L234A L235A).
T298 268-436 Sentence denotes It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4).